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Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the
Treatment of Carcinoid Syndrome
Matthew H. Kulke, Dieter Hörsch, Martyn E. Caplin, Lowell B. Anthony, Emily Bergsland, Kjell Öberg,
Staffan Welin, Richard R.P. Warner, Catherine Lombard-Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle,
Douglas Fleming, Pablo Lapuerta, Phillip Banks, Shanna Jackson, Brian Zambrowicz, Arthur T. Sands, and
Marianne Pavel
A B S T R A C T
Purpose
Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces
bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled
phase III study evaluated telotristat ethyl in this setting.
Patients and Methods
Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog
therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per
day orally during a 12-week double-blind treatment period. The primary end point was change from
baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat
ethyl 500 mg.
Results
Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were –0.81
for telotristat ethyl 250 mg (P , .001) and ‒0.69 for telotristat ethyl 500 mg (P , .001). At week 12,
mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat
ethyl 500 mg were –0.9, –1.7, and –2.1, respectively. Responses, predefined as a BM frequency
reduction $ 30% from baseline for $ 50% of the double-blind treatment period, were observed in
20%, 44%, and 42%of patients given placebo, telotristat ethyl 250mg, and telotristat ethyl 500mg,
respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole
acetic acid versus placebo at week 12 (P , .001). Mild nausea and asymptomatic increases in
gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up
of patients during the open-label extension revealed no new safety signals and suggested sustained
BM responses to treatment.
Conclusion
Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs,
treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant
reductions in BM frequency and urinary 5-hydroxyindole acetic acid.
J Clin Oncol 35:14-23. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Patients with advanced neuroendocrine tumors
(NETs) may develop carcinoid syndrome, a con-
dition associated with tumoral secretion of sero-
tonin and characterized by diarrhea, flushing,
bronchial constriction, and the development of
cardiac valvular fibrosis, which may lead to heart
failure.1,2 Diarrhea, one of the most prominent
symptoms of carcinoid syndrome, negatively af-
fects patients’ emotional well-being and social and
physical functioning.3 Serotonin is metabolized
into 5-hydyroxyindoleacetic acid (5-HIAA), a bio-
marker measurable in the urine and often used to
follow treatment response in patients with carci-
noid syndrome.4,5 High systemic serotonin
levels, as reflected by elevated urinary 5-HIAA
(u5-HIAA), most often in the setting of wide-
spread tumor metastases, are associated with
severe carcinoid syndrome, carcinoid heart
disease, and poor prognosis.2,6,7
Somatostatin analogs (SSAs), the standard
treatment for patients with carcinoid syndrome,
are an effective initial treatment, but patients may
develop recurrent symptoms during the course of
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their disease.4,8 Tryptophan hydroxylase (TPH), the rate-limiting
enzyme in serotonin synthesis, converts tryptophan to 5-
hydroxytryptophan, which is subsequently converted to serotonin.5
The hypothesis that inhibiting TPH may reduce symptoms of car-
cinoid syndrome was tested in 1967 by Engelman et al9 with par-
achlorophenylalanine. In that study, symptoms improved and u5-
HIAA levels were reduced. However, parachlorophenylalanine
crossed the blood-brain barrier, causing severe CNS-related
adverse effects, including depression.
Telotristat ethyl is a novel, oral, small-molecule TPH inhibitor
that has a high molecular weight and acidic moieties, which inhibit
it from crossing the blood-brain barrier.5,10 Two early studies in
patients with carcinoid syndrome suggested that telotristat etiprate,
the hippurate salt of telotristat ethyl, reduced bowel movement
(BM) frequency and decreased u5-HIAA without overt CNS ad-
verse effects.11,12 Although the name “telotristat etiprate” was
previously granted by the United States Adopted Names Council
and has been used in the literature,11,12 recent guidance from the
US Food and Drug Administration recommends using the name of
the neutral form rather than the name of the salt for drug products.
Therefore, telotristat ethyl is used herein. In this international,
multicenter, randomized, double-blind, placebo-controlled phase
III trial (TELESTAR), we assessed the safety and efficacy of telo-
tristat ethyl in patients with carcinoid syndrome not adequately
controlled with SSA therapy.
PATIENTS AND METHODS
Patients
Eligible patients were $18 years of age, had histopathologically con-
firmed, well-differentiated metastatic NETs, had a documented history of
carcinoid syndrome, were experiencing an average of four or more BMs per
day, and were receiving stable-dose SSAs (long-acting release [LAR], depot,
or infusion pump) for $ 3 months before enrollment. Patients with
u5-HIAA levels above or below the upper limit of normal (normal: 0 to
15 mg/24 hours13) and those with unknown values at baseline were allowed
to participate. Because of the risk of acute complications from severe di-
arrhea, patients experiencing more than 12 watery BMs per day associated
with volume contraction, dehydration, or hypotension, or showing evidence
of enteric infection were excluded. In addition, patients with a Karnofsky
performance status # 60%, a history of short bowel syndrome, or clinically
important baseline elevation in liver function tests were excluded. Patients
were also excluded if they had recently undergone tumor-directed therapy.
Additional exclusion criteria are described in the Data Supplement.
Study Design and Treatment
Patients entered a screening period of 3 or 4 weeks, depending upon
their SSA dose schedule (typically administered every 3 to 4 weeks),14 to
establish baseline symptoms. Patients were randomly assigned 1:1:1 to re-
ceive oral doses, three times per day for 12 weeks, of telotristat ethyl 250 mg,
telotristat ethyl 500 mg, or placebo. Patients continued to receive their
baseline SSA therapy for all 12 weeks. Rescue use of short-acting octreotide
and antidiarrheal agents was allowed and unrestricted. After this double-
blind treatment (DBT) period, all patients were offered treatment with
telotristat ethyl 500mg three times per day in a 36-week open-label extension
(OLE). Downward dose adjustment was allowed in cases of intolerability.
The OLE is currently ongoing. Conduct of the study was approved by the
institutional review board or ethics committee at each center, and the study
complied with Good Clinical Practice guidelines and the Declaration of
Helsinki. All patients provided written informed consent.
Efficacy and Safety Assessments
All primary and secondary efficacy assessments, except u5-HIAA,
were self-reported in daily electronic diaries. The primary end point of the
study was mean reduction from baseline in daily BMs averaged over
12 weeks. Key secondary end points included change from baseline in u5-
HIAA at week 12, the number of daily flushing episodes, and abdominal
pain severity (on a scale of 0 to 10) averaged over 12 weeks. Responders
were prespecified as patients experiencing a $ 30% reduction in BM
frequency (relative to baseline) for $ 50% of the DBT period. Additional
efficacy end points included change from baseline in the European Or-
ganisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC QLQ-C30) scores, rescue short-acting
SSA use, stool consistency, and the proportion of days with urgency to
defecate (Data Supplement). Patient use of over-the-counter antidiarrheals
was not tracked in this study.
Adverse events (AEs) were graded as mild, moderate, or severe (Data
Supplement). Depression-related AEs were events of special interest, and
a validated two-question case-finding instrument was administered to all
patients at each study visit.15 A pharmacokinetic analysis substudy was
performed in 40 patients (Data Supplement). The planned efficacy analyses
were based on the intent-to-treat population. However, a single patient
initially randomly assigned to receive telotristat ethyl 500 mg was sub-
sequently deemed a screen failure and was not treated. This same patient
was subsequently re-evaluated, found to meet all eligibility criteria, ran-
domly assigned a second time to telotristat ethyl 250 mg, and included in
the telotristat ethyl 250 mg group for analysis of efficacy and safety. The
safety population consisted of all patients who received at least one dose of
the study drug.
Statistical Analysis
A blocked Wilcoxon rank sum statistic (stratified by baseline u5-HIAA
levels) was used to evaluate the primary efficacy end point. The non-
parametric Hodges-Lehmann estimator was used to describe the magnitude
of the treatment effect. Parallel analyses were used for additional efficacy end
points, including change from baseline in u5-HIAA level, number of flushing
episodes, abdominal pain severity, EORTC QLQ-C30 scores, stool consis-
tency, and the proportion of days with urgency to defecate. A Bonferroni-
based multiple comparison procedure with restrictions on the order of
testing treatment group hypotheses was applied to control the local and
overall type I error probabilities (a = .05) for the primary and secondary
efficacy end points. A more detailed description of the statistical methods
used in this study is provided in the Data Supplement.
RESULTS
Patient Characteristics
From January 31, 2013, to March 4, 2015, 135 patients from
12 countries were randomly assigned to receive telotristat ethyl
250 mg or 500 mg three times per day or placebo three times per
day (Fig 1). Demographic and baseline characteristics were similar
among groups (Table 1); 43% of patients were receiving above-
label doses of SSAs, defined as a cumulative dose of . 30 mg
octreotide LAR or . 120 mg lanreotide over the course of
4 weeks.8,16 At baseline, mean daily BM frequency ranged from 5.2
to 6.1 counts per day andmean u5-HIAA levels ranged from 81.0 to
92.6 mg/24 hours across all treatment groups. More than 57% of
patients had u5-HIAA levels above the upper limit of normal.
Patient Disposition
In this study (N = 135), 45 patients received treatment in each
study arm. A total of 136 random assignments occurred; one
ascopubs.org/journal/jco © 2016 by American Society of Clinical Oncology 15
Telotristat Ethyl for the Treatment of Carcinoid Syndrome
Enrollment
Randomly allocated 1:1:1
(n = 135; 136 random allocations*)
Allocations (DBT)
Follow-up
Analysis
Allocated to telotristat ethyl
250 mg three times per day
  Received allocated
    intervention
  Did not receive
    allocated intervention
(n = 45)
(n = 45)
(n = 0)
Allocated to placebo
  Received allocated
    intervention
  Did not receive
    allocated intervention
(n = 45)
(n = 45)
(n = 0)
Allocated to telotristat ethyl
500 mg three times per day
  Received allocated
    intervention
  Did not receive
  allocated intervention*
(n = 46*)
(n = 45)
(n = 1)
Analyzed
  Excluded from analysis
(n = 45)
(n = 0)
Analyzed
  Excluded from analysis
(n = 45)
(n = 0)
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(n = 45)
(n = 0)
(n = 0)
(n = 4)
(n = 2)
(n = 0)
(n = 0)
(n = 1)
(n = 1)
Lost to follow-up
Discontinued intervention
in DBT period
  Adverse event†
  Death‡
  Physician decision
  Withdrawal of consent
  Other
(n = 0)
(n = 7)
(n = 3)
(n = 2)
(n = 1)
(n = 1)
(n = 0)
Lost to follow-up
Discontinued intervention
in DBT period
  Adverse event†
  Death‡
  Physician decision
  Withdrawal of consent
  Other
Lost to follow-up
Discontinued intervention
in DBT period
  Adverse event†
  Death‡
  Physician decision
  Withdrawal of consent
  Other
(n = 0)
(n = 8)
(n = 2)
(n = 1)
(n = 1)
(n = 3)
(n = 1)
Excluded
  Not meeting inclusion/met
    exclusion criteria
  Declined to participate or 
    withdrew consent
  Death
  Other reasons
(n = 39)
(n = 32)
(n = 3)
(n = 2)
(n = 2)
Allocations (OLE)§
Completed the DBT
Entered the OLE
(n = 38)
(n = 38)
Completed the DBT
Entered the OLE
(n = 41)
(n = 39)
Completed the DBT
Entered the OLE
(n = 38)
(n = 38)
All patients treated with
telotristat ethyl 500 mg
Lost to follow-up
Discontinued
intervention in the OLE
  Adverse event
  Death
  Lack of efficacy
  Physician decision
  Withdrawal of consent
  Other
(n = 0)
(n = 30)
(n = 9)
(n = 4)
(n = 5)
(n = 2)
(n = 7)
(n = 3)
Assessed for eligibility
(N = 175)
Fig 1. CONSORT diagram. Patient flow in the double-blind treatment (DBT) period of the TELESTAR study. (*) One patient initially randomly assigned to receive telotristat
ethyl 500 mg was designated a screen failure because of bruising found during physical examination. This patient was subsequently rescreened, met all eligibility criteria,
and was subsequently randomly assigned a second time to telotristat ethyl 250 mg. This patient was included in the telotristat ethyl 250 mg group for both efficacy and
safety analyses. (†) Additional adverse events leading to study discontinuation are fully described in Table 3. (‡) A total of five deaths occurred after random assignment, but
two patients (one each receiving placebo and telotristat ethyl 250 mg three times per day) previously withdrew from the study because of adverse events. (§) Patient flow
into the open-label extension (OLE) reflects data extracted from the interim clinical study report.
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patient initially randomly assigned to the telotristat ethyl 500 mg
group and deemed a screen failure was rescreened and sub-
sequently randomly assigned a second time to receive telotristat
ethyl 250 mg (Data Supplement). Forty-one patients (91.1%) and
38 patients (82.6%) in the telotristat ethyl 250 mg and 500 mg
groups, respectively, and 38 patients (84.4%) in the placebo group
completed the DBT period. Compliance, defined as receipt of 75%
to 125% of planned doses, was 93.3% and 86.7% in the telotristat
ethyl 250 mg and 500 mg groups, respectively, and 86.7% in the
placebo group. Use of short-acting rescue octreotide was slightly
higher in the placebo group than in patients receiving telotristat
ethyl (Appendix Fig A1, online only). At the time this article was
prepared, 115 patients entered the OLE, 56 completed it, and 29
were currently receiving treatment. Mean treatment exposure was
26.7 weeks (range, 1.7 to 38.3 weeks).
Efficacy
BM frequency. Treatment with telotristat ethyl at either dos-
age was associated with statistically significant reductions in BM
frequency over time compared with placebo (Fig 2A). The Hodges-
Lehmann estimator for patients receiving telotristat ethyl 250 mg
was 20.81 and 20.69 for those receiving telotristat ethyl 500 mg
(P , .001). The arithmetic mean reduction in daily BM frequency
from baseline toweek 12 was –1.7 –and –2.1 with the telotristat ethyl
250 mg and 500 mg, respectively, and –0.9 for the placebo (Fig 2B).
Individual patient responses during the DBT period are shown in
Figures 2C and 2D. In total, 44% and 42% of participants who
received telotristat ethyl 250 mg and 500 mg, respectively, were
classified as BM responders versus 20% of patients who received the
placebo. The odds ratios (ORs) were 3.49 (95%CI, 1.33 to 9.16) and
3.11 (95% CI, 1.20 to 8.10) for telotristat ethyl 250 mg and 500 mg,
respectively (Table 2). In the OLE, BM reductions were consistent
with results from the DBT period (Fig 2A).
u5-HIAA. In patients who were evaluable at baseline and
week 12, treatment with telotristat ethyl at either dosage was as-
sociated with statistically significant reductions in u5-HIAA levels
compared with placebo. The Hodges-Lehmann estimator was
–30.1 mg/24 hours and –33.8 mg/24 hours for telotristat ethyl
250 mg and 500 mg, respectively (P , .001 for both). At week 12,
arithmetic mean u5-HIAA levels decreased by 40.1 mg/24 hours
and by 57.7 mg/24 hours in the telotristat ethyl 250 mg and 500 mg
groups, respectively. The mean u5-HIAA levels increased in the
placebo group by 11.5 mg/24 hours at week 12. Individual patient
responses during the DBT period are shown in Figures 3A and 3B.
In a post hoc analysis of patients treated with telotristat ethyl, 78%
(n = 25) and 87% (n = 26) of patients in the 250 mg and 500 mg
groups, respectively, experienced a $ 30% decrease in u5-HIAA
levels compared with 10% (n = 3) in the placebo group.
Flushing and abdominal pain. Relatively few patients reported
having two ormore flushing episodes per day or abdominal pain (rating
of$3 of 10 in severity) at baseline (Table 1), and changes in these end
points did not reach statistical significance (Appendix Table A1).
Quality of life and other end points. EORTC QLQ-C30 di-
arrhea subscale scores, which were averaged over the DBT period,
improved by 19.2 points (on a scale of 0 to 100) and by 21.6 points
in the telotristat ethyl 250 mg and 500 mg groups, respectively, and
by only 8.5 points in the placebo group (P = .039 and P = .051 for
Table 1. Demographic and Baseline Characteristics of the Patient Population
Characteristic
Placebo (n 5 45)
Telotristat Ethyl (three times per day)
Total250 mg (n 5 45) 500 mg (n 5 45)
No. (%) Mean SD No. (%) Mean SD No. (%) Mean SD No. (%)
Age, years 63.3 8.7 62.4 9.1 64.9 9.0
Males 24 (53.3) 21 (46.7) 25 (55.6)
Daily BM frequency 5.2 1.4 6.1 2.1 5.8 2.0
Minimum, maximum 3.5-9.0 3.5-13.0 3.6-12.5
SSA therapy at study entry*
Octreotide LAR 30 (66.7) 40 (88.9) 33 (73.3)
Lanreotide depot 15 (33.3) 5 (11.1) 12 (26.7)
SSA use above labeled dose† 18 (40.0) 19 (42.2) 21 (46.7)
u5-HIAA
# ULN (0-15 mg/24 hours) 12 (26.7) 12 (26.7) 12 (26.7)
. ULN (. 15 mg/24 hours) 26 (57.8) 26 (57.8) 26 (57.8)
Unknown 7 (15.6) 7 (15.6) 7 (15.6)
Baseline values, mg/24 hours 81.0 (n 5 44) 92.6 (n 5 42) 89.5 (n 5 44)
CgA at baseline, mg/L 885.7 (n 5 42) 503.2 (n 5 43) 1,203.4 (n 5 43)
Cutaneous flushing episodes per day 1.8 1.9 2.8 3.7 2.7 3.4
Total No. of patients with $ 2
episodes per day
52 (38.5)
Abdominal pain score 2.5 2.3 2.6 2.3 2.6 2.2
$ 3 of 10 17 (37.8) 17 (37.8) 18 (40.0)
No. of patients with severe abdominal
pain, score of $ 3 of 10
52 (38.5)
Abbreviations: BM, bowel movement; CgA, chromogranin-A; LAR, long-acting release; SD, standard deviation; SSA, somatostatin analog; u5-HIAA, urinary
5-hydroxyindoleacetic acid; ULN, upper limit of normal.
*At study entry, patients received aminimum SSA dose of octreotide LAR 30mg or lanreotide depot 120mg once every 4weeks or the highest tolerated dose. Includes
patients who received SSA therapy via a subcutaneous continuous infusion pump.
†Above-label dosing was defined as a cumulative dose of . 30 mg octreotide LAR or . 120 mg lanreotide over the course of 4 weeks.8,16
ascopubs.org/journal/jco © 2016 by American Society of Clinical Oncology 17
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telotristat ethyl 250 mg and 500 mg, respectively.). No significant
treatment group differences were observed in the nausea and
vomiting subscale. No overall differences in the global health status
subscale were observed between treatment arms, although patients
classified as BM responders reported modest improvements in
overall quality of life compared with nonresponders in all three
treatment arms (Appendix Table A2). Some evidence that telo-
tristat ethyl may also improve stool consistency, reduce the urgency
to defecate, and reduce rescue short-acting octreotide use was
observed (Appendix Table A1; Appendix Fig A1). Pharmacokinetic
models also support a dose response to treatment of both u5-HIAA
and BM frequency (Data Supplement).
Safety
The overall incidence of treatment-emergent adverse events
(TEAEs) across the three treatment arms was similar (Table 3; Ap-
pendix Table A3). A higher incidence of nausea was noted in patients
in the telotristat ethyl 500 mg group (31.1%) compared with patients
in the telotristat ethyl 250 mg group or the placebo group (13.3% and
11.1%, respectively). One patient receiving placebo discontinued the
study drug because of nausea; however, no patients receiving telotristat
ethyl discontinued because of nausea. Dose-related increases in hepatic
enzymes, particularly gamma-glutamyl transferase, were observed in
both telotristat ethyl groups (Table 3). In the DBT period, depression-
related AEs, including depression, depressed mood, and decreased
interest, occurred during treatment in 6.7%, 6.7%, and 15.6% of
patients in the placebo, telotristat ethyl 250 mg, and 500 mg groups,
respectively. However, no patient reporting depression required ini-
tiation of new antidepressant therapy, and no cases of depression
resulted in treatment discontinuation. In the OLE, among patients
who crossed over from placebo to telotristat ethyl 500 mg, there was
only one new report of decreased interest, but no new reports of
depression or depressed mood were made between weeks 12 and 24
(Appendix Table A4).
DISCUSSION
In this randomized, double-blind, placebo-controlled phase III
study in patients with carcinoid syndrome not adequately
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controlled on SSA therapy, treatment with the oral TPH inhibitor
telotristat ethyl was associated with statistically significant re-
ductions in BM frequency compared with placebo. Marked de-
creases in u5-HIAA were also associated with treatment.
Although the overall incidence of TEAEs was similar across all
treatment groups, nausea and elevated gamma-glutamyl trans-
ferase were reported more often in patients receiving telotristat
ethyl. In patients receiving subsequent treatment in the OLE,
reductions in BM frequency seemed to be sustained, and no new
safety signals were observed. To our knowledge, this study
represents one of the largest randomized placebo-controlled
studies conducted to date to assess symptom control in pa-
tients with carcinoid syndrome.
SSAs, including octreotide and lanreotide, are widely used for the
treatment of carcinoid syndrome, but not all patients achieve complete
symptom control.4,17,18 Moreover, patients with carcinoid syndrome
often live for years and may develop recurrent symptoms.4,6 There
are few other treatment options, and the development of new
treatments for carcinoid syndrome has proved challenging, in part
because of the rarity of the condition and the lack of new drug
candidates.19-21
BM frequency is a useful end point in carcinoid syndrome
studies because of its impact on patient function3 and well-being.
A decrease of approximately three BMs per day (from a baseline of
five to six BMs per day) was reported with octreotide LAR in
patients with carcinoid syndrome.17 In this study, in patients
experiencing diarrhea despite concomitant SSA therapy, BM
frequency decreased by approximately two BMs per day with
telotristat ethyl.
We performed a prespecified responder analysis, defining
responders as patients experiencing $ 30% decrease in BM fre-
quency for $ 50% of the DBT period, thereby measuring both
magnitude and duration of response.10,11 More than 40% of pa-
tients treated with telotristat ethyl were responders versus 20% of
patients treated with placebo.
Consistent with these observations, we also observed improve-
ments in quality of life using the EORTCQLQ-C30 diarrhea subscale.
No differences in the EORTC QLQ-C30 global health scores were
observed. In fact, these scores were similar across all three treatment
arms, suggesting that no quality of life detriment was associated
with treatment. Interestingly, only minimal changes in overall
EORTC QLQ-C30 global health scores were observed in previous
studies in patients with NETs who received SSAs, suggesting that
this domain may not be particularly sensitive in this patient
population.22-24
The BM response rate of 20% in the placebo group was
a somewhat unexpected observation in our study. Although the
placebo effect is well documented in clinical trials,25,26 BM
frequency is a relatively robust and objective end point and, in
theory, should not be susceptible to subjective reporting. Use of
short-acting rescue SSA therapy was somewhat more common
in the placebo arm of this study and may have partially
accounted for our observations. In addition, variability in the
absorption of long-acting SSAs, differences in use of other
antidiarrheal medications, and dietary changes may have
contributed to the responses observed in the placebo group.
Treatment with telotristat ethyl significantly reduced u5-HIAA
levels, suggesting effective TPH inhibition. u5-HIAA levels may vary
for other reasons, and in prior studies of patients with NETs,$ 30%
reduction in secretory biomarkers has been used as a measure of
treatment efficacy to reduce the risk of capturing natural variability.27
In this study,. 78% of patients treated with telotristat ethyl (at either
dosage) experienced a$ 30% decrease in u5-HIAA levels versus 10%
in the placebo group. The broader clinical significance of de-
creasing systemic serotonin levels, as determined by u5-HIAA
levels, in patients with carcinoid syndrome has not been fully
established. However, serotonin stimulates fibroblast prolifer-
ation and has been linked to cardiac valvular fibrosis in patients
with carcinoid syndrome.28 Serotonin may also mediate mes-
enteric fibrosis often observed in patients with small intestine
NETs.29 Future studies examining whether these complications
of carcinoid syndrome can be prevented by reducing serotonin
production with telotristat ethyl are warranted.
Similar reductions in BM frequency were observed at both
telotristat ethyl dosages; however, over time, numerically greater
reductions in BM frequency were observed with telotristat ethyl
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Fig 3. Percentage change from baseline in urinary 5-hydyroxyindoleacetic acid (u5-HIAA) levels at week 12. (A and B) Distribution of individual patient responses as
percentage change from baseline in u5-HIAA levels at week 12 for (A) telotristat ethyl 250 mg 3 times per day (tid) and (B) telotristat ethyl 500 mg three times per day. In
patients treated with telotristat ethyl, 78% (n = 25) and 84% (n = 26) of patients in the 250mg and 500mg groups, respectively, experienced a$ 30% decrease in u5-HIAA
levels compared with 10% (n = 3) in the placebo group. The dashed line represents a commonly used cutoff of $ 30% reduction in secretory biomarkers of carcinoid
syndrome.27
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500 mg from weeks 7 to 12. Reductions in u5-HIAA levels and in
the EORTC QLQ-C30 diarrhea subscale, the proportion of days
with the urgency to defecate, and improvements in stool consis-
tency were also numerically greater with telotristat ethyl 500 mg.
Telotristat ethyl 500 mg demonstrated a favorable long-term
tolerability profile, suggesting that this dose may be beneficial to
patients not adequately responding to initial treatment with
telotristat ethyl 250 mg.
Telotristat ethyl was generally well tolerated in this patient
population. Increases in transaminases and nausea were observed in
previous studies of telotristat ethyl.11,12 In this study, these events did
not result in treatment discontinuation in patients randomly assigned
to receive telotristat ethyl. Telotristat ethyl did not appear to be as-
sociated with an increased incidence of serious TEAEs. Preclinical
studies suggest that telotristat ethyl does not have significant CNS
penetration.5 In this study, a higher incidence of depression-related
events was observed in patients who received telotristat ethyl 500 mg
than in patients who received placebo; however, incidences in patients
who received telotristat ethyl 250mg and placebowere nearly identical.
Most events resolved on study, and no new antidepressant ther-
apies were initiated. In the current interim analysis of the OLE,
rates of depression-related events have been relatively low. How-
ever, these data may be subject to some degree of selection bias and
should be interpreted with caution. Additional follow-up in the
Table 3. TEAEs Reported in the DBT Period
Category Placebo (n = 45)
Telotristat Ethyl (three times per day)
250 mg (n = 45) 500 mg (n = 45)
Any TEAE 39 (86.7) 37 (82.2) 42 (93.3)
Study discontinuation as a result of TEAE* 6 (13.3) 3 (6.7) 3 (6.7)
TEAE resulting in death† 3 (6.7) 1 (2.2) 1 (2.2)
Selected AEs occurring in $ 5% of patients
in any study arm by system organ class
and preferred term‡
GI disorders
Nausea 5 (11.1) 6 (13.3) 14 (31.1)
Abdominal pain 8 (17.8) 5 (11.1) 10 (22.2)
Vomiting 4 (8.9) 2 (4.4) 5 (11.1)
Abdominal distension 3 (6.7) 2 (4.4) 1 (2.2)
Diarrhea 3 (6.7) 3 (6.7) 0
Dyspepsia 3 (6.7) 1 (2.2) 1 (2.2)
General disorders and administration site conditions
Fatigue 4 (8.9) 4 (8.9) 7 (15.6)
Infections and infestations
Nasopharyngitis 1 (2.2) 2 (4.4) 3 (6.7)
Pneumonia 0 0 3 (6.7)
AEs relating to investigations
Increased gamma-glutamyl transferase§ 0 4 (8.9) 4 (8.9)
Increased ALT|| 0 1 (2.2) 3 (6.7)
Increased alkaline phosphatase¶ 0 0 3 (6.7)
Metabolism and nutrition disorders
Decreased appetite 2 (4.4) 3 (6.7) 7 (15.6)
Hypokalemia 3 (6.7) 3 (6.7) 5 (11.1)
Nervous system disorders
Headache 2 (4.4) 5 (11.1) 4 (8.9)
Dizziness 2 (4.4) 0 4 (8.9)
Memory impairment 3 (6.7) 0 1 (2.2)
Psychiatric disorders
Depression-related# 3 (6.7) 3 (6.7) 7 (15.6)
Confusional state 0 0 3 (6.7)
Respiratory, thoracic, and mediastinal disorders
Dyspnea 0 2 (4.4) 4 (8.9)
Cough 1 (2.2) 1 (2.2) 3 (6.7)
Vascular disorders (new or worsening)
Flushing 2 (4.4) 3 (6.7) 3 (6.7)
NOTE. All data are presented as No. (%).
Abbreviations: AE, adverse event; DBT, double-blind treatment; TEAE, treatment-emergent adverse event.
*TEAEs leading to study discontinuation were anemia, cardiac arrest, nausea, vomiting, eructation, dyspepsia, chills, fatigue, general health deterioration, dehydration,
disease progression (five patients), sepsis, rash, and increased gamma-glutamyl transferase.
†All deaths occurred in the setting of advanced metastatic disease.
‡AEs were graded according to a standard severity grading scheme as mild, moderate, or severe.
§Mean changes from baseline at week 12 in gamma-glutamyl transferase (U/L6 standard deviation [SD]) for all patients studied were 4.46 31.6 in the placebo group,
130.0 6 204.4 in the telotristat ethyl 250 mg three times per day group, and 242.4 6 358.1 in the telotristat ethyl 500 mg three times per day group.
||Mean changes from baseline to week 12 in ALT (U/L6 SD) for all patients studied were –0.16 6.2 in the placebo group, 7.16 16.4 in the telotristat ethyl 250 mg three
times per day group, and 17.4 6 42.6 in the telotristat ethyl 500 mg three times per day group.
¶Mean changes from baseline to week 12 in alkaline phosphatase (U/L6 SD) for all patients studied were 16.16 57.6 in the placebo group, 22.86 41.8 in the telotristat
ethyl 250 mg three times per day group, and 57.5 6 140.8 in the telotristat ethyl 500 mg three times per day group.
#Depression-related AEs include depression, depressed mood, and decreased interest.
ascopubs.org/journal/jco © 2016 by American Society of Clinical Oncology 21
Telotristat Ethyl for the Treatment of Carcinoid Syndrome
ongoing OLE and evaluation of safety data in a separate ongoing
phase III study (clinical trial information: NCT02063659) are
planned.
In conclusion, treatment with the oral TPH inhibitor telo-
tristat ethyl (250 mg or 500 mg three times per day) was generally
safe and well tolerated and was associated with a significant de-
crease in BM frequency in patients with carcinoid syndrome re-
ceiving treatment with SSAs. The associated decreases in u5-HIAA
provide evidence that telotristat ethyl effectively decreases sero-
tonin production and has the potential to mitigate serotonin-
mediated complications in this patient population. These obser-
vations suggest that telotristat ethyl represents a potential new
treatment approach for patients with carcinoid syndrome.
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Fig A1. Mean daily use of rescue short-acting somatostatin analog (SSA) therapy
in the double-blind treatment period. Some evidence that treatment with telotristat
ethyl decreased the use of rescue short-acting SSA therapy was observed during
the double-blind treatment period.
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Table A1. Additional Secondary End Points of the DBT Period
Variable
Placebo (n = 45)
Telotristat Ethyl (three times per day)
250 mg (n = 45) 500 mg (n = 45)
Mean (SD) P Mean (SD) P Mean (SD) P
Flushing
Change from baseline in daily flushing episodes averaged
over 12 weeks, counts per day
20.16 (1.16) 20.30 (1.31) 20.53 (1.34)
Arithmetic mean treatment difference — 20.13 20.36
Hodges-Lehmann estimator* — — 0.036 .39 0.00 .84
Abdominal pain
Change from baseline in abdominal pain averaged over 12
weeks, points†
20.23 (1.16) 20.49 (1.44) 20.33 (1.18)
Arithmetic mean treatment difference — 20.26 20.11
Hodges-Lehmann estimator* — — 20.17 .28 20.05 .87
Daily rescue short-acting SSA use
Change from baseline in use of short-acting SSAs, averaged
over 12 weeks, injections per day
0.18 20.11 0.03
Arithmetic mean treatment difference — 20.30 20.15
Hodges-Lehmann estimator* — — 0 .19 0 .16
Stool consistency
Change from baseline in stool consistency averaged over 12
weeks, points
20.22 (0.48) 20.26 (0.47) 20.36 (0.41)
Arithmetic mean treatment difference — 20.05 20.15
Hodges-Lehmann estimator* — — 20.09 .57 20.15 .052
Urgency to defecate
Proportion of days 0.75 (0.29) 0.67 (0.34) 0.60 (0.31)
Arithmetic mean treatment difference — 20.09 20.15
Hodges-Lehmann estimator* — — 20.02 .35 –0.13 .006
Abbreviations: DBT, double-blind treatment; SD, standard deviation; SSA, somatostatin analog.
*Nonparametric measure derived as the median of all possible differences between the groups.
†Abdominal pain based on patient rating using an 11-point scale: 0, no pain; 10, worst pain ever experienced.
Table A2. Quality-of-Life Outcomes During the DBT Period
EORTC QLQ-C30 Subscale
Placebo (n = 45)
Telotristat Ethyl (three times per day)
250 mg (n = 45) 500 mg (n = 45)
No. of Patients Mean (SD) No. of Patients Mean (SD) No. of Patients Mean (SD)
Global health status/QoL* 39 22.0 (18.3) 39 1.7 (19.1) 37 22.1 (21.4)
BM responders† 9 3.7 (30.4) 16 7.8 (20.5) 14 1.2 (17.9)
BM nonresponders† 25 25.0 (18.0) 20 26.2 (20.8) 20 0.8 (22.8)
Diarrhea‡ 39 28.5 (21.9) 39 219.2 (29.3) 37 221.6 (27.2)
BM responders† 9 222.2 (33.3) 16 222.9 (35.9) 14 233.3 (34.6)
BM nonresponders† 25 28.0 (27.7) 20 220.0 (29.4) 20 28.3 (18.3)
Nausea and vomiting‡ 39 22.4 (13.5) 39 22.4 (20.3) 38 20.9 (21.0)
Insomnia‡ 39 27.7 (25.9) 40 3.3 (18.9) 38 4.4 (33.3)
Physical functioning* 39 21.2 (13.3) 40 20.2 (11.1) 38 22.1 (11.8)
Role functioning* 39 21.3 (16.8) 39 7.7 (28.8) 38 1.1 (26.9)
Emotional functioning* 39 0.5 (13.7) 39 0.7 (16.4) 37 1.6 (15.5)
Cognitive functioning* 39 0.0 (20.8) 39 22.4 (13.2) 37 20.7 (12.6)
Social functioning* 39 0.4 (15.8) 39 2.6 (23.4) 37 23.2 (20.8)
Fatigue‡ 39 0.4 (18.7) 40 22.4 (22.2) 38 22.9 (20.1)
Pain‡ 39 1.7 (19.6) 40 25.2 (28.4) 38 24.4 (29.5)
Dyspnea‡ 39 1.7 (18.7) 40 21.7 (20.9) 38 4.4 (24.4)
Appetite loss‡ 38 27.5 (25.9) 40 1.3 (25.7) 38 20.9 (23.2)
Constipation‡ 38 0.9 (3.8) 39 2.6 (7.2) 38 5.7 15.6)
Financial difficulties‡ 38 21.3 (19.1) 39 25.1 (15.4) 36 2.8 (18.5)
NOTE. EORTC QLQ-C30 subscales show mean change from baseline averaged over 12 weeks (points), unless otherwise specified.
Abbreviations: BM, bowel movement; DBT, double-blind treatment; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30; QoL, quality of life; SD, standard deviation.
*For all total/domain scores, a higher functional score indicates a more favorable outcome.
†Change from baseline at week 12 (points).
‡For all individual/symptom scores, a higher score indicates a less favorable patient outcome.
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Table A3. All AEs Occurring in $ 5% of Patients in Any Study Arm in the DBT Period
AE (system organ class preferred term) Placebo (n = 45)
Telotristat Ethyl (three times per day)
Total (N = 135)250 mg (n = 45) 500 mg (n = 45)
GI disorders
Nausea 5 (11.1) 6 (13.3) 14 (31.1) 25 (18.5)
Abdominal pain 8 (17.8) 5 (11.1) 10 (22.2) 23 (17.0)
Vomiting 4 (8.9) 2 (4.4) 5 (11.1) 11 (8.1)
Upper abdominal pain 0 2 (4.4) 5 (11.1) 7 (5.2)
Abdominal distension 3 (6.7) 2 (4.4) 1 (2.2) 6 (4.4)
Diarrhea 3 (6.7) 3 (6.7) 0 6 (4.4)
Flatulence 1 (2.2) 3 (6.7) 2 (4.4) 6 (4.4)
Dyspepsia 3 (6.7) 1 (2.2) 1 (2.2) 5 (3.7)
General disorders and administration site conditions
Fatigue 4 (8.9) 4 (8.9) 7 (15.6) 15 (11.1)
Asthenia 3 (6.7) 2 (4.4) 1 (2.2) 6 (4.4)
Peripheral edema 1 (2.2) 3 (6.7) 1 (2.2) 5 (3.7)
Pyrexia 2 (4.4) 3 (6.7) 0 5 (3.7)
Infections and infestations
Nasopharyngitis 1 (2.2) 2 (4.4) 3 (6.7) 6 (4.4)
Pneumonia 0 0 3 (6.7) 3 (2.2)
AEs relating to investigations
Increased gamma-glutamyl transferase* 0 4 (8.9) 4 (8.9) 8 (5.9)
Increased ALT† 0 1 (22.2) 3 (6.7) 4 (3.0)
Increased alkaline phosphatase‡ 0 0 3 (6.7) 3 (2.2)
Metabolism and nutrition disorders
Decreased appetite 2 (4.4) 3 (6.7) 7 (15.6) 12 (8.9)
Hypokalemia 3 (6.7) 3 (6.7) 5 (11.1) 11 (8.1)
Nervous system disorders
Headache 2 (4.4) 5 (11.1) 4 (8.9) 11 (8.1)
Dizziness 2 (4.4) 0 4 (8.9) 6 (4.4)
Memory impairment 3 (6.7) 0 1 (2.2) 4 (3.0)
Psychiatric disorders
Depression-related§ 3 (6.7) 3 (6.7) 7 (15.6) 13 (9.6)
Confusional state 0 0 3 (6.7) 3 (2.2)
Respiratory, thoracic, and mediastinal disorders
Dyspnea 0 2 (4.4) 4 (8.9) 6 (4.4)
Cough 1 (2.2) 1 (2.2) 3 (6.7) 5 (3.7)
Epistaxis 0 0 3 (6.7) 3 (2.2)
Vascular disorders (new or worsening)
Flushing 2 (4.4) 3 (6.7) 3 (6.7) 8 (5.9)
NOTE. Adverse events (AEs) were graded according to a standard severity grading scheme as mild, moderate, or severe. All data are presented as No. (%).
Abbreviation: DBT, double-blind treatment.
*Mean changes from baseline at week 12 in gamma-glutamyl transferase (U/L6 standard deviation [SD]) for all patients studied were 4.46 31.6 in the placebo group,
130.0 6 204.4 in the telotristat ethyl 250 mg three times per day group, and 242.4 6 358.1 in the telotristat ethyl 500 mg three times per day group.
†Mean changes from baseline to week 12 in ALT (U/L6 SD) for all patients studied were –0.16 6.2 in the placebo group, 7.16 16.4 in the telotristat ethyl 250mg three
times per day group, and 17.4 6 42.6 in the telotristat ethyl 500 mg three times per day group.
‡Mean changes from baseline to week 12 in alkaline phosphatase (U/L6 SD) for all patients studied were 16.16 57.6 in the placebo group, 22.86 41.8 in the telotristat
ethyl 250 mg three times per day group, and 57.5 6 140.8 in the telotristat ethyl 500 mg three times per day group.
§Depression-related AEs include depression, depressed mood, and decreased interest.
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Table A4. Summary of TEAEs Reported During the OLE
Category
OLE* (n = 115)
No. %
Any TEAE 105 91.3
Any serious TEAE† 36 31.3
Study discontinuation as a result of TEAE‡ 14 12.2
TEAE resulting in death§ 8 7.0
Selected key AEs
Any depression-related AE¶ 17 15.0
Nausea 23 20.0
Increased gamma-glutamyl transferase 7 6.1
Increased alanine aminotransferase 4 3.5
Increased alkaline phosphatase 5 4.3
Abbreviations: AE, adverse event; OLE, open-label extension; TEAE, treatment-
emergent adverse event.
*Patients were initiated at 500 mg telotristat ethyl three times per day. Mean
treatment exposure was 11.3 weeks in the double-blind treatment period and
26.7 weeks in the OLE.
†AEs were considered serious if they involved death, a life-threatening AE,
inpatient hospitalization, a persistent or significant incapacity, substantial dis-
ruption in the ability to conduct normal life function, or a congenital anomaly or
birth defect.
‡TEAEs leading to study discontinuation in the OLE were supraventricular
tachycardia, disease progression (five patients), abdominal distension, con-
stipation, GI hemorrhage, hematemesis, large intestine perforation, asthenia,
fatigue, general physical health deterioration, hepatomegaly, peritonitis, sepsis,
increased liver enzymes, decreased weight, decreased appetite, dehydration,
mental confusion, cognitive disorder, renal failure, and urticaria.
§None of the deaths occurring during the OLEwere considered related to study
drug. The deaths were generally attributable to the progression or complication
of the underlying disease.
¶Depression-related AEs include depression, depressed mood, and decreased
interest.
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